Pacific Edge Appoints Mark Green as Independent Director

Company Announcement
4 May 2021

PACIFIC EDGE APPOINTS MARK GREEN AS INDEPENDENT DIRECTOR

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to welcome Mark Green as an Independent
Director, effective from 10 May 2021.

Mark is an experienced corporate finance professional, with approximately 25 years of experience in the
Australasian capital, corporate and financial markets. He was an Executive Director for Investment Banking at
Goldman Sachs where he worked for nearly 20 years and has been involved in many large prominent New Zealand
transactions including the IPOs of Meridian, Mighty River Power and Vector. Mark is a Director of a number of
entities including being Chair of Astrolab VC Investment Committee and a Director of Mariposa Holdings (a large
charitable organisation).

Mark said: “Pacific Edge is an exciting New Zealand company seeking to lead the way in cancer diagnostics. It is a
company that has sought to protect its intellectual property and to add value not only to its shareholders and other
corporate stakeholders but also to New Zealand. It is a privilege to be involved with such a company.”

Chair of Pacific Edge, Chris Gallaher, commented: "We are very pleased to welcome Mark to the Board
which continues the Board rejuvenation process that we have underway. He has significant capital markets and
corporate finance experience gained over a long career with Goldman Sachs and has recently returned from Tokyo
where his family was based for the last two and a half years.

Mark's appointment fills a skills need identified by the Board and he will be a strong contributor to both the Board
and the company as we continue on our growth pathway.”

Mark Green has been appointed by the current Pacific Edge Directors, as permitted under Pacific Edge’s
constitution. He will hold office until Pacific Edge’s 2021 Annual Meeting at which time he will offer himself for
election by shareholders. The Board has determined that Mark is an Independent Director.

ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

Company Announcement
4 May 2021



ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.